Frequently Asked Questions:
The global trientine hydrochloride market was valued at USD 715.2 Million in 2022.
The trientine hydrochloride market is expected to grow at a CAGR of 7.9% between 2023 and 2030, reaching USD 1314.01 Million in 2030.
Wilson’s disease is the leading segment by indication, holding over 58% share in value in 2022.
The adult patients segment governs the demand for trientine hydrochloride globally, holding a massive share of over 62% in 2022.
The oral capsules segment will post the highest CAGR in the projection period.
North America is fueling the growth of the trientine hydrochloride industry, with over one-third of its share in 2022.
The top players include Albany Molecular Research Inc, SMIQ Pharma, Sigma-Aldrich Co. LLC, Valeant Pharmaceuticals International Inc, SGPharma Pvt Ltd., Shaanxi TOP Pharm Chemical Co. Ltd (Top Pharm Chemical Group), Green Stone Swiss Co. Ltd, and Others.
The increasing prevalence of wilson’s disease and advancements in treatment formulations and delivery methods are the major market drivers.
Limited disease awareness and diagnosis, high treatment costs, and accessibility issues are the major market restraints.
The opportunities include personalized medicine and pharmacogenomics, as well as expansion in emerging markets for wilson’s disease treatment.